Treatment of Drug Susceptible Pulmonary Tuberculosis.
10.4046/trd.2015.78.3.161
- Author:
Hong Joon SHIN
1
;
Yong Soo KWON
Author Information
1. Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea. yongsu3@gmail.com
- Publication Type:Review
- Keywords:
Tuberculosis;
Antitubercular Agents;
Fluoroquinolones;
Combination Therapy;
Drug-Related Side Effects and Adverse Reactions
- MeSH:
Antitubercular Agents;
Drug-Related Side Effects and Adverse Reactions;
Fluoroquinolones;
Humans;
Incidence;
Korea;
Radiography, Thoracic;
Recurrence;
Sputum;
Tuberculosis;
Tuberculosis, Pulmonary*
- From:Tuberculosis and Respiratory Diseases
2015;78(3):161-167
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tuberculosis (TB) remains a major global health problem, and the incidence of TB cases has not significantly decreased over the past decade in Korea. The standard short course regimen is highly effective against TB, but requires multiple TB-specific drugs and a long treatment duration. Recent studies using late-generation fluoroquinolones and/or high-dose rifapentine-containing regimens to shorten the duration of TB treatment showed negative results. Extending the treatment duration may be considered in patients with cavitation on the initial chest radiograph and positivity in sputum culture at 2 months of treatment for preventing TB relapse. Current evidence does not support the use of fixed-dose combinations compared to separate drugs for the purpose of improving treatment outcomes. All patients receiving TB treatment should be monitored regularly for response to therapy, facilitation of treatment completion, and management of adverse drug reactions. Mild adverse effects can be managed with symptomatic therapy and changing the timing of the drug administration, but severe adverse effects require a discontinuation of the offending drugs.
